[1]
Meunier, B. Hybrid molecules with a dual mode of action: Dream or reality? Acc. Chem. Res., 2008, 41(1), 69-77.
[2]
Yang, S-Y. Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug Discov. Today, 2010, 15(11-12), 444-450.
[3]
Shaveta; Mishra, S.; Singh, P. Hybrid molecules: The privileged scaffolds for various pharmaceuticals. Eur. J. Med. Chem., 2016, 124, 500-536.
[4]
Muregi, F.W.; Ishih, A. Next-generation antimalarial drugs: Hybrid molecules as a new strategy in drug design. Drug Dev. Res., 2010, 71(1), 20-32.
[5]
Morphy, R.; Rankovic, Z. Designed multiple ligands: An emerging drug discovery paradigm. J. Med. Chem., 2005, 48(21), 6523-6543.
[6]
Alovero, F.; Nieto, M.; Mazzieri, M.R.; Then, R.; Manzo, R.H. Mode of action of sulfanilyl fluoroquinolones. Antimicrob. Agents Chemother., 1998, 42(6), 1495-1498.
[7]
Christiaans, J.A.M.; Timmerman, H. Cardiovascular hybrid drugs: Combination of more than one pharmacological property in one single molecule. Eur. J. Pharm. Sci., 1996, 4(1), 1-22.
[8]
Locher, H.H.; Caspers, P.; Bruyere, T.; Schroeder, S.; Pfaff, P.; Knezevic, A.; Keck, W.; Ritz, D. Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of clostridium difficile infections. Antimicrob. Agents Chemother., 2014, 58(2), 901-908.
[9]
Gorityala, B.K.; Guchhait, G.; Goswami, S.; Fernando, D.M.; Kumar, A.; Zhanel, G.G.; Schweizer, F. Hybrid antibiotic overcomes resistance in P. aeruginosa by enhancing outer membrane penetration and reducing efflux. J. Med. Chem., 2016, 59(18), 8441-8455.
[10]
Shavit, M.; Pokrovskaya, V.; Belakhov, V.; Baasov, T. Covalently linked kanamycin - Ciprofloxacin hybrid antibiotics as a tool to fight bacterial resistance. Bioorg. Med. Chem., 2017, 25(11), 2917-2925.
[11]
Singla, P.; Luxami, V.; Paul, K. Triazine as a promising scaffold for its versatile biological behavior. Eur. J. Med. Chem., 2015, 102, 39-57.
[12]
Berube, G. An overview of molecular hybrids in drug discovery. Expert Opin. Drug Discov., 2016, 441, 1-25.
[13]
Faruck, M.O.; Yusof, F.; Chowdhury, S. An overview of antifungal peptides derived from insect. Peptides, 2016, 80, 80-88.
[14]
Cuenca-Estrella, M. Combinations of antifungal agents in therapy - What value are they? J. Antimicrob. Chemother., 2004, 54(5), 854-869.
[15]
Parente-Rocha, J.A.; Bailao, A.M.; Amaral, A.C.; Taborda, C.P.; Paccez, J.D.; Borges, C.L.; Pereira, M. Antifungal resistance, metabolic routes as drug targets, and new antifungal agents: An overview about endemic dimorphic fungi. Mediators Inflamm., 2017, 2017, 1-16.
[16]
Jiang, Z.; Wang, Y.; Wang, W.; Wang, S.; Xu, B.; Fan, G.; Dong, G.; Liu, Y.; Yao, J.; Miao, Z.; Zhang, W.; Sheng, C. Discovery of highly potent triazole antifungal derivatives by heterocycle-benzene bioisosteric replacement. Eur. J. Med. Chem., 2013, 64, 16-22.
[17]
Walsh, T.J.; Dixon, D.M. Spectrum of Mycoses. In:Medical Microbiology; Baron, S., Ed.; University of Texas Medical Branch at Galveston: Galveston, TX, 1996.
[18]
Graybill, J.R.; Burgess, D.S.; Hardin, T.C. Key issues concerning fungistatic versus fungicidal drugs. Eur. J. Clin. Microbiol. Infect. Dis., 1997, 16(1), 42-50.
[19]
Michael, A.; Pfaller, M.D. Antifungal drug resistance: Mechanisms, epidemiology, and consequences for treatment. Am. J. Med., 2012, 125(1), 3-13.
[20]
Abe, F.; Hiraki, T. Mechanistic role of ergosterol in membrane
rigidity and cycloheximide resistance in Saccharomyces cerevisiae.
Biochimica et Biophysica Acta - Biomembranes,2009, 1788(3),
743-752.
[21]
Wheat, L.J.; Cloud, G.; Johnson, P.C.; Connolly, P.; Goldman, M.; Le Monte, A.; Fuller, D.E.; Davis, T.E.; Hafner, R. The AIDS clinical trials group. The mycoses study group of niaid. clearance of fungal burden during treatment of disseminated histoplasmosis with liposomal amphotericin b versus itraconazole. Antimicrob. Agents Chemother., 2001, 45(8), 2354-2357.
[22]
Kathiravan, M.K.; Salake, A.B.; Chothe, A.S.; Dudhe, P.B.; Watode, R.P.; Mukta, M.S.; Gadhwe, S. The biology and chemistry of antifungal agents: A review. Bioorg. Med. Chem., 2012, 20(19), 5678-5698.
[23]
Odds, F.C.; Brown, A.J.P.; Gow, N.A.R. Antifungal agents: Mechanisms of action. Trends Microbiol., 2003, 11(6), 272-279.
[24]
Cohen, B.E. Amphotericin B toxicity and lethality: A tale of two channels. Int. J. Pharm., 1998, 162(1-2), 95-106.
[25]
Saravolatz, L.D.; Ostrosky-Zeichner, L.; Marr, K.A.; Rex, J.H.; Cohen, S.H.; Amphotericin, B. Time for a new ‘Gold Standard. Clin. Infect. Dis., 2003, 37(3), 415-425.
[26]
Mistro, S.; MacIel, I.D.M.; De Menezes, R.G.; Maia, Z.P.; Schooley, R.T.; Badaro, R. Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis. Clin. Infect. Dis., 2012, 54(12), 1774-1777.
[27]
Hakki, M.; Staab, J.F.; Marr, K.A. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob. Agents Chemother., 2006, 50(7), 2522-2524.
[28]
Schäfer-Korting, M.; Schoellmann, C.; Korting, H.C. Fungicidal activity plus reservoir effect allow short treatment courses with terbinafine in tinea pedis. Skin Pharmacol. Physiol., 2008, 21(4), 203-210.
[29]
Ma, H.; Sui, F.; Zhao, Q.; Zhang, N.; Sun, Y.; Xian, J.; Jiao, M.; Liu, Y.; Wang, Z. Lewis base-catalyzed cyanation of Morita-Baylis-Hillman carbonates. Synthesis of allylamine derivatives. Tetrahedron Lett., 2017, 58(35), 3410-3414.
[30]
Yu, S.; Chai, X.; Hu, H.; Yan, Y.; Guan, Z.; Zou, Y.; Sun, Q.; Wu, Q. Synthesis and antifungal evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14α-demethylase. Eur. J. Med. Chem., 2010, 45(10), 4435-4445.
[31]
da Silva, C.M.; da Silva, D.L.; Modolo, L.V.; Alves, R.B.; de Resende, M.A.; Martins, C.V.B.; de Fatima, A. Schiff bases: A short review of their antimicrobial activities. J. Adv. Res., 2011, 2(1), 1-8.
[32]
Cuenca-Estrella, M.; Bernal-Martinez, L.; Buitrago, M.J.; Castelli, M.V.; Gomez-Lopez, A.; Zaragoza, O.; Rodriguez-Tudela, J.L. Update on the epidemiology and diagnosis of invasive fungal infection. Int. J. Antimicrob. Agents, 2008, 32(2), 143-147.
[33]
Lewis, R.E.; Kontoyiannis, D.P.; Darouiche, R.O.; Raad, I.I.; Prince, R.A. Antifungal activity of amphotericin B, fluconazole, and voriconazole in an in vitro model of Candida catheter-related bloodstream infection. Antimicrob. Agents Chemother., 2002, 46(11), 3499-3505.
[34]
Borate, H.B.; Sawargave, S.P.; Chavan, S.P.; Chandavarkar, M.A.; Iyer, R.; Tawte, A.; Rao, D.; Deore, J.V.; Kudale, A.S.; Mahajan, P.S.; Kangire, G.S. Novel hybrids of fluconazole and furanones: Design, synthesis and antifungal activity. Bioorg. Med. Chem. Lett., 2011, 21(16), 4873-4878.
[35]
Šenel, P.; Tichotova, L.; Votruba, I.; Buchta, V.; Spulak, M.; Kunes, J.; Nobilis, M.; Krenk, O.; Pour, M. Antifungal 3,5-disubstituted furanones: From 5-Acyloxymethyl to 5-alkylidene derivatives. Bioorg. Med. Chem., 2010, 18, 1988-2000.
[36]
kowalsky, S.F.; Dixon, D.M. Fluconazole: A new antifungal agent. Clin. Pharm., 1991, 10(3), 179-194.
[37]
Borate, H.B.; Maujan, S.R.; Sawargave, S.P.; Chandavarkar, M.A.; Vaiude, S.R.; Joshi, V.A.; Wakharkar, R.D.; Iyer, R.; Kelkar, R.G.; Chavan, S.P.; Kunte, S.S. Fluconazole analogues containing 2H-1, 4-benzothiazin-3 (4H)-one or 2H-1, 4-benzoxazin-3 (4H)-one moieties, a novel class of anti-Candida agents. Bioorg. Med. Chem. Lett., 2010, 20(2), 722-725.
[38]
Tiwari, R.; Miller, P.A.; Chiarelli, L.R.; Mori, G.; Sarkan, M.; Centarova, I.; Cho, S.; Mikusova, K.; Franzblau, S.G.; Oliver, A.G.; Miller, M.J. Design, syntheses, and anti-TB activity of 1,3-benzothiazinone azide and click chemistry products inspired by BTZ043. ACS Med. Chem. Lett., 2016, 7(3), 266-270.
[39]
Dudley, D.A.; Bunker, M.A.; Chi, L.; Cody, W.L.; Holland, D.R.; Ignasiak, D.P.; Janiczek-Dolphin, N.; McClanahan, T.B.; Mertz, T.E.; Narasimhan, L.S.; Rapundalo, S.T.; Trautschold, J.A.; Van Huis, C.A.; Edmunds, J.J. Rational design, synthesis, and biological activity of benzoxazinones as novel factor Xa inhibitors. J. Med. Chem., 2000, 43(22), 4063-4070.
[40]
Fang, X.F.; Li, D.; Tangadanchu, V.K.; Gopala, L.; Gao, W.W.; Zhou, C.H. Novel potentially antifungal hybrids of 5-flucytosine and fluconazole: Design, synthesis and bioactive evaluation. Bioorg. Med. Chem. Lett., 2017, 27(22), 4964-4969.
[41]
Imperi, F.; Massai, F.; Facchini, M.; Frangipani, E.; Visaggio, D.; Leoni, L.; Brangozi, A.; Visca, P. Repurposing the antimycotic drug flucytosine for suppression of Pseudomonas aeruginosa pathogenicity. Proc. Natl. Acad. Sci. USA, 2013, 110(18), 7458-7463.
[42]
Eilard, T.; Alestig, K.; Wahlen, P. Treatment of disseminated candidiasis with 5-Fluorocytosine. J. Infect. Dis., 1974, 130(2), 155-159.
[43]
Vermes, A.; Guchelaar, H-J.; Dankert, J. Flucytosine: A review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J. Antimicrob. Chemother., 2000, 42(6), 171-179.
[44]
Biot, C.; François, N.; Maciejewski, L.; Brocard, J.; Poulain, D. Synthesis and antifungal activity of a ferrocene-fluconazole analogue. Bioorg. Med. Chem. Lett., 2000, 10(8), 839-841.
[45]
Ornelas, C. Application of ferrocene and its derivatives in cancer research. New J. Chem., 2011, 35(10), 1973-1985.
[46]
Chohan, Z.H. Antibacterial and antifungal ferrocene incorporated dithiothione and dithioketone compounds. Bioorganomettal. Chem., 2006, 20(2), 112-116.
[47]
Yu. S. Chai. X.; Wang, Y.; Cao, Y.; Zhang, J.; Wu Q., Zhang, D.; Jiang Y.; Yan T.; Sun Q. Triazole derivatives with improved in vitro antifungal activity over azole drugs. Drug Des. Devel. Ther., 2014, 383-390.
[48]
Mochizuki, A.; Nakamoto, Y.; Naito, H.; Uoto, K.; Ohta, T. Design, synthesis, and biological activity of piperidine diamine derivatives as factor Xa inhibitor. Bioorg. Med. Chem. Lett., 2008, 18(2), 782-787.
[49]
Caldas, E.D.; Conceição, M.H.; Miranda, M.C.C.; De Souza, L.C.K.R.; Lima, J.F. Determination of dithiocarbamate fungicide residues in food by a spectrophotometric method using a vertical disulfide reaction system. J. Agric. Food Chem., 2001, 49(10), 4521-4525.
[50]
Woodrow, J.E.; Seiber, J.N.; Fitzell, D. Analytical method for the dithiocarbamate fungicides ziram and mancozeb in Air: Preliminary field results. J. Agric. Food Chem., 1995, 43(6), 1524-1529.
[51]
Zou, Y.; Yu, S.; Li, R.; Zhao, Q.; Li, X.; Wu, M.; Huang, T.; Chai, X.; Hu, H.; Hu, Q. Synthesis, antifungal activities and molecular docking studies of novel 2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl dithiocarbamates. Eur. J. Med. Chem., 2014, 74, 366-374.
[52]
Küçük, H.B.; Yusufoğlu, A.; Mataracı, E.; Döşler, S. Synthesis and biological activity of new 1,3-dioxolanes as potential antibacterial and antifungal compounds. Molecules, 2011, 16(8), 6806-6815.
[53]
Miniyar, P.B.; Mahajan, A.A.; Mokale, S.N.; Shah, M.U.; Kumar, A.S.; Chaturbhuj, G.U. Triazole hybrids as new type of anti-fungal agents. Arab. J. Chem., 2017, 10(3), 295-299.
[54]
Salahuddin; Shaharyar, M.; Mazumder, A. Benzimidazoles : A biologically active compounds. Arab. J. Chem., 2017, 10(S1), S157-S173.
[55]
Ouahrouch, A. Ighachane. H.; Taourirte, M.; Engels, J.W.; Sedra, M.H.; Lazrek, H.B. Benzimidazole-1, 2, 3-triazole hybrid molecules: Synthesis and evaluation for antibacterial/antifungal activity. Archiv der Pharmazie,, 2014, 347(10), 748-755.
[56]
Pramod, K.; Ansari, S.H.; Ali, J. Eugenol: A natural compound with versatile pharmacological actions. Nat. Prod. Commun., 2010, 5(12), 1999-2006.
[57]
Lokwani, P.; Nagori, B.P.; Batra, N.; Goyal, A.; Gupta, S.; Singh, N. Benzoxazole: The molecule of diverse biological activities. J. Chem. Pharm. Res., 2011, 3(3), 302-311.
[58]
de Carvalho, L.I.S.; Alvarenga, D.J.; do Carmo, L.C.F.; de Oliveira, L.G.; Silva, N.C.; Dias, A.L.T.; Coelho, L.F.L.; de Souza, T.B.; Dias, D.F.; Carvalho, D.T. Antifungal activity of new eugenol-benzoxazole hybrids against Candida spp. J. Chem., 2017, 1-8.
[59]
Iman, M.; Peroomian, T.; Davood, A.; Amini, M.; Sardari, S.; Azerang, P. Design, synthesis and evaluation of new azoles as antifungal agents: A molecular hybridization approach. Pharm. Chem. J., 2016, 49(10), 687-693.
[60]
Singh, K.; Kaur, H.; Chibale, K.; Balzarini, J.; Little, S.; Bharatam, P.V. 2-Aminopyrimidine based 4-Aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure -activity relationship and mode of action studies. Eur. J. Med. Chem., 2012, 52, 82-97.
[61]
Ahmad, A.; Husain, A. Synthesis, antimicrobial and antitubercular activities of some novel pyrazoline derivatives. J. Saudi Chem. Soc., 2016, 20(5), 577-584.
[62]
Montoya, A.; Quiroga, J.; Abonia, R.; Derita, M.; Sortino, M.; Ornelas, A.; Zacchino, S.; Insuasty, B. Hybrid molecules containing a 7-chloro-4-aminoquinoline nucleus and a substituted 2-pyrazoline with antiproliferative and antifungal activity. Molecules, 2016, 21(8), 969-987.
[63]
Shaikh, M.H.; Subhedar, D.D.; Khan, K.; Sangshetti, J.N.; Nawale, L.; Arkile, M.; Sarkar, D.; Shingate, B.B. Synthesis of novel triazole-incorporated isatin derivatives as antifungal, antitubercular, and antioxidant agents and molecular docking study. J. Heterocycl. Chem., 2017, 54(1), 413-421.
[64]
Raj, R.; Singh, P.; Singh, P.; Gut, J.; Rosenthal, P.J.; Kumar, V.N. Lal, V. Kumar, A. Sarswat, S. Jangir. Azide-alkyne cycloaddition en route IH- 1,2,3-triazole-tethered 7-chloroquinoline-isatin chimeras: Synthesis and antimalarial evaluaton. Eur. J. Med. Chem., 2013, 62, 590-592.
[65]
Shaikh, S.K.J.; Kamble, R.R.; Somagond, S.M.; Devarajegowda, H.C.; Dixit, S.R.; Joshi, S.D. Tetrazolylmethyl quinolines: Design, docking studies, synthesis, anticancer and antifungal analyses. Eur. J. Med. Chem., 2017, 128, 258-273.
[66]
Joseph, A.; Shah, C.S.; Kumar, S.S.; Aex, A.T.; Maliyakkal, N.; Moorkoth, S.; Mahew, J.E. Synthesis, in vitro anticancer and antioxidant activity of thiadiazole substituted thiazolidin-4-ones. Acta Pharm., 2013, 63(3), 397-408.
[67]
Levent, S.; Kaya, C.B.; Sağlık, B.N.; Osmaniye, D.; Acar, C.U.; Atlı, Ö.; Özkay, Y.; Kaplancıklı, Z.A. Synthesis of oxadiazole-thiadiazole hybrids and their anticandidal activity. Molecules, 2017, 22(11), 2004.
[68]
Can Baser, K.H. Biological and pharmacological activities of carvacrol and carvacrol bearing essential oils. Curr. Pharm. Des., 2008, 1(29), 3106-3119.
[69]
Pete, U.D.; Zade, C.M.; Bhosale, J.D.; Tupe, S.G.; Chaudhary, P.M.; Dikundwar, A.G.; Bendre, R.S. Hybrid molecules of carvacrol and benzoyl urea/thiourea with potential applications in agriculture and medicine. Bioorg. Med. Chem. Lett., 2012, 22(17), 5550-5554.
[70]
Xu, L.; Wu, Y.; Zhao, X.; Zhang, W. In: The Study on Biological
and Pharmacological Activity of Coumarins In: Proceedings of
Asia-pacific Energy equipment Engineering Research Conference,
Zuhani, China, June 13-14, 2015; Carl J., Ed . Atlantis Press, 2015;
pp. 135-138
[71]
Sposato, L.A.; Fustinoni, O. Latrogenic neurology. In:Handbook of Clinical Neurology; Biller, J.; Ferro, J.M., Eds.; Elsevier Science B.V: Amsterdam, 2014, Vol. 121, pp. 1635-1671.
[72]
Vekariya, R.H.; Patel, K.D.; Rajani, D.P.; Rajani, S.D.; Patel, H.D. A one pot, three component synthesis of coumarin hybrid thiosemicarbazone derivatives and their antimicrobial evolution. J. Associat. Arab Univ. Basic Appl. Sci., 2017, 23, 10-19.
[73]
Desai, N.C.; Satodiya, H.M.; Rajpara, K.M.; Joshi, V.V.; Vaghani, H.V. Microwave assisted synthesis of new coumarin based 3-cyanopyridine scaffolds bearing sulfonamide group having antimicrobial activity. Indian J. Chem., 2013, 52B(7), 904-914.
[74]
Mohana, K.N.; Prasanna, B.N. Synthesis and biological activity of some pyrimidine derivatives. Drug Invent. Today, 2013, 5(3), 216-222.
[75]
Laxmi, S.V.; Kuarm, B.S.; Rajitha, B. Synthesis and antimicrobial activity of coumarin pyrazole pyrimidine 2, 4, 6 (1H, 3H, 5H) triones and thioxopyrimidine4, 6 (1H, 5H) diones. Med. Chem. Res., 2013, 22(2), 768-774.
[76]
Naim, J.M.; Alam, O.; Nawaz, F.; Alam, M.J.; Alam, P. Current status of pyrazole and its biological activities. J. Pharm. Bioallied Sci., 2016, 8, 2-17.
[77]
Thakrar, S.; Bavishi, A.; Radadiya, A.; Vala, H.; Parekh, S.; Bhavsar, D.; Chaniyara, R.; Shah, A. An Efficient microwave‐assisted synthesis and antimicrobial activity of novel 2‐amino 3‐cyano pyridine derivatives using two reusable solid acids as catalysts. J. Heterocycl. Chem., 2014, 51(3), 555-561.
[78]
Reddy, K.R.; Mamatha, R.; Babu, M.S.; Shiva, K.K.; Jayaveera, K.N.; Narayanaswamy, G. Synthesis and antimicrobial activities of some triazole, thiadiazole, and oxadiazole substituted coumarins. J. Heterocycl. Chem., 2014, 51(1), 132-137.
[79]
Puttaraju, K.B.; Shivashankar, K.; Mahendra, M.; Rasal, V.P.; Vivek, P.N.; Rai, K.; Chanu, M.B. Microwave assisted synthesis of dihydrobenzo [4, 5] imidazo [1, 2-a] pyrimidin-4-ones; synthesis, in vitro antimicrobial and anticancer activities of novel coumarin substituted dihydrobenzo [4, 5] imidazo [1, 2-a] pyrimidin-4-ones. Eur. J. Med. Chem., 2013, 69, 316-322.
[80]
Boregowda, P.; Kalegowda, S.; Rasal, V.P.; Eluru, J.; Koyye, E. Synthesis and Biological Evaluation of 4-(3-Hydroxy-benzofuran-2-yl) coumarins. Org. Chem. Int., 2014, 27, 2014.
[81]
Dongamanti, A.; Bommidi, V.L.; Arram, G.; Sidda, R. Microwave-assisted synthesis of (E)-7-[(1-benzyl-1H-1, 2, 3-triazol-4-yl) methoxy]-8-(3-arylacryloyl)-4-methyl-2H-chromen-2-ones and their antimicrobial activity. Heterocycl. Commun., 2014, 20(5), 293-298.
[82]
Tiwari, S.V.; Seijas, J.A.; Vazquez-Tato, M.P.; Sarkate, A.P.; Karnik, K.S.; Nikalje, A.P. Facile synthesis of novel coumarin derivatives, antimicrobial analysis, enzyme assay, docking study, ADMET prediction and toxicity study. Molecules, 2017, 22(7), 1172-1190.
[83]
Irfan, M.; Aneja, B.; Yadava, U.; Khan, S.I.; Manzoor, N.; Daniliuc, C.G.; Abid, M. Synthesis, QSAR and anticandidal evaluation of 1, 2, 3-triazoles derived from naturally bioactive scaffolds. Eur. J. Med. Chem., 2015, 93, 246-254.
[84]
Irfan, M.; Alam, S.; Manzoor, N.; Abid, M. Effect of quinoline based 1, 2, 3-triazole and its structural analogues on growth and virulence attributes of Candida albicans. PLoS One, 2017, 12(4), 0175710.
[85]
Mohana, K.N.; Mallesha, L.; Gurudatt, D.M. Synthesis and antimicrobial activity of 5-aminoquinoline and 3-amino phenol derivatives. Inter. J. Drug Design Discov., 2011, 2, 584-590.
[86]
Amir, M.; Javed, S.A.; Hassan, M.Z. Synthesis and antimicrobial activity of pyrazolinone and pyrazole analogues containing quinoline moiety. Indian J. Chem., 2013, 52, 1493-1499.
[87]
Kumar, S.; Bawa, S.; Drabu, S.; Panda, B.P. Design and synthesis of 2-chloroquinoline derivatives as non-azoles antimycotic agents. Med. Chem. Res., 2011, 20(8), 1340-1348.
[88]
Desai, N.C.; Rajpara, K.M.; Joshi, V.V.; Vaghani, H.V.; Satodiya, H.M. Synthesis, characterization and antimicrobial screening of hybrid molecules containing quinoline, pyrimidine and morpholine analogues. J. Chem. Sci., 2013, 125(2), 321-333.
[89]
Desai, N.C.; Patel, B.Y.; Dave, B.P. Synthesis and antimicrobial activity of novel quinoline derivatives bearing pyrazoline and pyridine analogues. Med. Chem. Res., 2017, 26(1), 109-119.
[90]
Singh, H.; Nand, B.; Sindhu, J.; Khurana, J.M.; Sharma, C.; Aneja, K.R. Efficient one pot synthesis of xanthene-triazole-quinoline/ phenyl conjugates and evaluation of their antimicrobial activity. J. Braz. Chem. Soc., 2014, 25(7), 1178-1193.
[91]
Sidoryk, K.; Świtalska, M.; Jaromin, A.; Cmoch, P.; Bujak, I.; Kaczmarska, M.; Wietrzyk, J.; Dominguez, E.G.; Żarnowski, R.; Andes, D.R.; Bańkowski, K. The synthesis of indolo [2, 3-b] quinoline derivatives with a guanidine group: Highly selective cytotoxic agents. Eur. J. Med. Chem., 2015, 105, 208-219.
[92]
Kumar, M.P. Synthesis and antifungal activity screening of some novel 7-substituted-2-hydroxy-quinoline schiff bases. J. Appl. Pharm. Res., 2016, 4(4), 5-9.
[93]
Shah, N.M.; Patel, M.P.; Patel, R.G. Synthesis of a novel class of some biquinoline pyridine hybrids via one-pot, three-component reaction and their antimicrobial activity. J. Chem. Sci., 2012, 124(3), 669-677.
[94]
Desai, N.C.; Dodiya, A.M. Synthesis, characterization and in vitro antimicrobial screening of quinoline nucleus containing 1, 3, 4-oxadiazole and 2-azetidinone derivatives. J. Saudi Chem. Soc., 2014, 18(5), 425-431.
[95]
Zaheer, Z.; Khan, F.A.K.; Sangshetti, J.N.; Patil, R.H.; Lohar, K.S. Novel amalgamation of phthalazine-quinolines as biofilm inhibitors: One-pot synthesis, biological evaluation and in silico ADME prediction with favorable metabolic fate. Bioorg. Med. Chem. Lett., 2016, 26(7), 1696-1703.
[96]
Perokovic, V.P.; Ribic, R.; Prugovecki, B.; Matkovic-calogovic, D.; Tomic, C. An efficient synthesis of novel adamantane ß-amino Acid. Croat. Chem. Acta, 2012, 85(4), 419-423.
[97]
Hassan, G.S.; El-Emam, A.A.; Gad, L.M.; Barghash, A.E. Synthesis, antimicrobial and antiviral testing of some new 1-adamantyl analogues. Saudi Pharm. J., 2010, 18(3), 123-128.
[98]
Kadi, A.A.; El-Brollosy, N.R.; Al-Deeb, O.A.; Habib, E.E.; Ibrahim, T.M.; El-Emam, A.A. Synthesis, antimicrobial, and anti-inflammatory activities of novel 2-(1-adamantyl)-5-substituted-1,3,4-oxadiazoles and 2-(1-adamantylamino)-5-substituted-1,3,4-thiadiazoles. Eur. J. Med. Chem., 2007, 42(2), 235-242.
[99]
El-Emam, A.A.; Al-Tamimi, A.M.; Al-Omar, M.A.; Alrashood, K.A.; Habib, E.E. Synthesis and antimicrobial activity of novel 5-(1-adamantyl)-2-aminomethyl-4-substituted-1, 2, 4-triazoline-3-thiones. Eur. J. Med. Chem., 2013, 68, 96-102.
[100]
Al-Wahaibi, L.H.; Hassan, H.M.; Abo-Kamar, A.M.; Ghabbour, H.A.; El-Emam, A.A. Adamantane-Isothiourea hybrid derivatives: Synthesis, characterization, in vitro antimicrobial, and in vivo hypoglycemic activities. Molecules, 2017, 22(5), 710.
[101]
Ačimovič, J.; Rozman, D. Steroidal triterpenes of cholesterol synthesis. Molecules, 2013, 18(4), 4002-4017.
[102]
Radwan, A.A.; Alanazi, F.K. Targeting cancer using cholesterol conjugates. Saudi Pharm. J., 2014, 22(1), 3-16.
[103]
Loncle, C.; Brunel, J.M.; Vidal, N.; Dherbomez, M.; Letourneux, Y. Synthesis and antifungal activity of cholesterol-hydrazone derivatives. Eur. J. Med. Chem., 2004, 39(12), 1067-1071.
[104]
Dybowski, B.; Jabłońska, O.; Radziszewski, P.; Gromadzka-Ostrowska, J.; Borkowski, A. Ciprofloxacin and furagin in acute cystitis: comparison of early immune and microbiological results. Int. J. Antimicrob. Agents, 2008, 31(2), 130-134.
[105]
Piplani, M.; Rana, A.C.; Sharma, P.C. Synthesis, characterization and evaluation of prodrugs of ciprofloxacin clubbed with benzothiazoles through N-Mannich base approach. Chem. Biol. Lett., 2016, 3(2), 52-57.
[106]
Perez-Vizcaino, F.; Duarte, J.; Santos-Buelga, C. The flavonoid paradox: Conjugation and deconjugation as key steps for the biological activity of flavonoids. J. Sci. Food Agric., 92(9), 1822-
1825.
[107]
Xiao, Z.P.; Wang, X.D.; Wang, P.F.; Zhou, Y.; Zhang, J.W.; Zhang, L.; Zhou, J.; Zhou, S.S.; Ouyang, H.; Lin, X.Y.; Mustapa, M. Design, synthesis, and evaluation of novel fluoroquinolone-flavonoid hybrids as potent antibiotics against drug-resistant microorganisms. Eur. J. Med. Chem., 2014, 80, 92-100.
[108]
Jubie, S.; Rajeshkumar, R.; Yellareddy, B.; Siddhartha, G.; Sandeep, M.; Surendrareddy, K.; Dushyanth, H.S.; Elango, K. Microwave assisted synthesis of some novel benzimidazole substituted fluoroquinolones and their antimicrobial evaluation. J. Pharm. Sci. Res., 2010, 2, 69-76.
[109]
Papich, M.G. Saunders Handbook of Veterinary, 4th ed; Elsevier: Amsterdam, 2016.
